The European Commission has awarded approval to Novo Nordisk’s extended half-life factor VIII therapy Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A in adolescent and adult patients, the drugmaker has revealed.
Specifically, the approval covers “the prophylaxis and on-demand treatment of bleeding as well as for surgical procedures”.
